SynthesisPloS one2023
Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.
Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Tranexamic acid in spontaneous intracerebral hemorrhage: an updated systematic review and meta-analysis of randomized controlled trials.Annals of medicine · 2026Pooled it
- Tranexamic acid in spontaneous intracerebral hemorrhage: a meta-analysis.European journal of medical research · 2025Pooled it
- Efficacy and safety of tranexamic acid administration for subarachnoid hemorrhage: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Tranexamic Acid for Acute Bleeding in Severely Traumatized Patients: Mortality, Neurological Outcomes, and Thromboembolic Risk.Deutsches Arzteblatt international · 2026Review
- Article
- Perioperative anemia and patient blood management in neurosurgery and neurocritical care: a narrative review.Journal of anesthesia, analgesia and critical care · 2026Review
- Decoding spontaneous intracerebral hemorrhage: mechanistic breakthroughs and disruptive revolution in pharmacological treatment.Experimental & molecular medicine · 2026Review
- Determining the optimal hematoma volume-based thresholds for surgical and medical strategies in basal ganglia hemorrhage.Neurosurgical review · 2025Article
- Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial.Frontiers in neurology · 2025Article
- Review
- Clinical Study on the Use of Botulinum Toxin for Blepharospasm and Hemifacial Spasm.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
- The use of Tranexamic Acid in Case of Patient with Intracerebral Hemorrhage After a Coronary Procedure-Case Report.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial.
methodThe PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model.
resultsTwenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I2 = 0%, P < .001; TBI: MD -4.82, 95%CI -8.06 to -1.58, I2 = 0%, P = .004). For subarachnoid hemorrhage (SAH) patients, it significantly decreased the risk of hydrocephalus (OR 1.23, 95%CI 1.01 to 1.50, I2 = 0%, P = .04) and rebleeding (OR, 0.52, 95%CI 0.35 to 0.79, I2 = 56% P = .002). There was no significance in modified Rankin Scale, Glasgow Outcome Scale 3-5, mortality, deep vein thrombosis, pulmonary embolism, or ischemic stroke/transient ischemic.
conclusionTranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.